Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Explore this paper's citation graph
Summary
Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and in nine patients examined, tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
- Type
- article
- Published
- 2010-06-01
- Cited by
- 2,873
- References
- 19
- Access
- Open access
- OpenAlex
- https://openalex.org/W2010121426
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1222022
Keywords
Medicine, Pharmacodynamics, Tolerability, Nivolumab, Melanoma
References
- Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
- Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
- Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
- Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
- Epitope landscape in breast and colorectal cancer.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
- Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
- B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
- Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
- PD-1 and its ligands in tolerance and immunity.
Cited by
- L’immunothérapie : une nouvelle approche dans la prise en charge du cancer de prostate résistant à la castration
- Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance.
- Immunomodulating antibodies and drugs for the treatment of hematological malignancies
- Therapeutic cancer vaccines: current status and moving forward.
- Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
- Role of the PD-1 Pathway in the Immune Response
- The unfolding treatment landscape for men with castration-resistant prostate cancer
- Cancer immunotherapy: accomplishments to date and future promise.
- Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
- Advances and future directions in the targeting of HER2-positive breast cancer: Implications for the future
- Targeted immunotherapy for non-small cell lung cancer.
- PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
- Role of the Tumor Microenvironment in Breast Cancer
- Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals
- Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma
- Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone
- Risk of Bias and Heterogeneity.
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
- The inflammatory microenvironment and microbiome in prostate cancer development
Related papers
- A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
- Severe infusion reaction due to nivolumab: A case report
- P2.04-39 Clinical Characteristics of Long-Term Survivors with Nivolumab in Previously Treated Advanced NSCLC from Real World Data
- C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
- P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab: Topic: IT
- Radiological identification of rapid progressions in advanced NSCLC patients treated with nivolumab.
- Phase II study on lapatinib in advanced EGFR-positive chordoma.
- Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.
- Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.